GELSECTAN®IBS, 60 caps

Description

GELSECTAN® IBS

Gelsectan reduces diarrhea, abdominal pain, abdominal tension, swelling, and gas by restoring normal bowel function. Irritable bowel syndrome (IBS) with diarrhea, as well as symptoms caused by intestinal hypersensitivity or medicine. Gelsectan protects the mucosa of the intestine and boosts the number of healthy bifidobacteria in the gut.

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by recurrent chronic abdominal pain and altered bowel habits. It affects daily activity and work productivity, and is linked to a significant healthcare economic burden, as well as a poor quality of life and psycho-affective profile.

For chronic and recurrent diarrhea and abdominal pain

Recommended Intake

Take 1-2 capsules twice a day (in the morning before breakfast and in the evening before supper) for 2-4 weeks, depending on the severity of the symptoms. The treatment can be administered as a maintenance treatment if necessary.

Liquid should be used to swallow the capsule.

GELSECTAN® contains pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), which contains XG, pea protein and tannins (PPT) from grape seed extract, and xylo-oligosaccharides (XOS), and is capable of restoring intestinal permeability and improving gastrointestinal symptoms.

GELSECTAN® (xyloglucan, pea protein and tannins, xylo-oligosaccharides) is a medical device that has both protective and prebiotic effects on the intestinal mucosa, restoring intestinal permeability and improving gastrointestinal symptoms in adult patients with irritable bowel syndrome by controlling diarrhoea, abdominal pain, and bloating.

IBS affects about 4% of the global population 3 and is significantly more prevalent in women than in men. The pathophysiology of IBS includes genetic vulnerability, gastrointestinal motility, visceral hypersensitivity, increased intestinal permeability, immune system, low-grade inflammation, alterations in the intestinal microbiota, and food sensitivity.

Ingredients

Xyloglucan, vegetable proteins (pea protein and grape seed extract) and xylo-oligosaccharides.

Warnings/ Caution

Gluten-free, milk-free, yeast-free, does not contain ingredients of animal origin.

There are no recognized adverse effects. The product is only for those over the age of 18.

Pea allergy patients should avoid this remedy.

If your symptoms persist, are severe, or the diagnosis is unclear, see your doctor, especially if you are an elderly patient.

Despite the fact that there are no known negative effects, it is recommended that you avoid using the medication during pregnancy or breast-feeding unless your healthcare provider advises otherwise.

CE marked healthcare device.

Srorage

Keep at room temperature until the expiration date on the package.

References

Mearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016;18:S0016-5085(16)00222–5. doi:10.1053/j.gastro.2016.02.031

Soncini M, Stasi C, Usai Satta P, et al.; AIGO. IBS clinical management in Italy: the AIGO survey. Dig Liver Dis. 2019;51(6):782–789. doi:10.1016/j.dld.2018.10.006

Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. doi:10.1053/j.gastro.2020.04.014

Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367(17):1626–1635. doi:10.1056/NEJMra1207068

Portincasa P, Moschetta A, Baldassarre G, et al. Pan-enteric dysmotility, impaired quality of life and alexithymia in a large group of patients meeting ROME II criteria for irritable bowel syndrome. World J Gastroenterol. 2003;9(10):2293–2299. doi:10.3748/wjg.v9.i10.2293

Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122(5):1500–1511. doi:10.1053/gast.2002.32978

Bellini M, Gambaccini D, Stasi C, et al. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20(27):8807–8820. doi:10.3748/wjg.v20.i27.8807

Lucak S, Chang L, Halpert A, et al. Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol. 2017;10(2):253–275. doi:10.1177/1756283X16663396

Ford AC, Sperber AD, Corsetti M, et al. Irritable bowel syndrome. Lancet. 2020;396(10263):1675–1688. doi:10.1016/S0140-6736(20)31548-8

Piqué N, Gómez-Guillén MDC, Montero MP. Xyloglucan, a plant polymer with barrier protective properties over the mucous membranes: an overview. Int J Mol Sci. 2018;19(3):673. doi:10.3390/ijms19030673

Oshima T, Miwa H. Gastrointestinal mucosal barrier function and diseases. J Gastroenterol. 2016;51(8):768–778. doi:10.1007/s00535-016-1207-z

Gnessi L, Bacarea V, Marusteri M, et al. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial. BMC Gastroenterol. 2015;15(1):153. doi:10.1186/s12876-015-0386-z

Eutamene H, Beaufrand C, Harkat C, et al. The role of mucoprotectants in the management of gastrointestinal disorders. Expert Rev Gastroenterol Hepatol. 2018;12(1):83–90. doi:10.1080/17474124.2018.1378573

Trifan A, Burta O, Tiuca N, et al. Efficacy and safety of gelsectan for diarrhoea-predominant irritable bowel syndrome: a randomised, crossover clinical trial. United European Gastroenterol J. 2019;7(8):1093–1101. doi:10.1177/2050640619862721

Urakawa H, Mimura M, Kajiwara K. Diversity and versatility of plant seed xyloglucan. Trends Glycosci Glycotechnol. 2002;14(80):355–376. doi:10.4052/tigg.14.355

Kulkarni AD, Joshi AA, Patil CL, et al. Xyloglucan: a functional biomacromolecule for drug delivery applications. Int J Biol Macromol. 2017;104(Pt A):799–812. doi:10.1016/j.ijbiomac.2017.06.088

Santos J, Musta V, Luca CM, et al. Randomized, placebo-controlled trial of xyloglucan and gelose for the treatment of acute diarrhea in children. Expert Rev Gastroenterol Hepatol. 2021;15(3):325–331. doi:10.1080/17474124.2021.1833715